Detailansicht

Wissensnetz

Person

Steffen Koschmieder (1971-)

Arzt

Name	Steffen Koschmieder
Zeit	1971- (Lebensdaten)
Ort	Deutschland
Beruf	Arzt (charakteristischer Beruf)
Weitere Angaben	Diss. Fachbereich Medizin
Datensatztyp	Person
GND-Nummer	120495015
Datensatz-ID	120495015
Beteiligt an alle anzeigen Cell Adhesion and Local Cytokine Control on Protein‐Functionalized PNIPAM‐co‐AAc Hydrogel Microcarriers Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms Cell Adhesion and Local Cytokine Control on Protein‐Functionalized PNIPAM‐co‐AAc Hydrogel Microcarriers Elucidating the complexity of the interferon alpha response and clonal heterogeneity in polycythemia vera patients using single-cell RNA sequencing Regulation of lipocalin 2 expression and function in BCR-ABL- and JAK2V617F-positive myeloproliferative neoplasms SIngle cell level Genotyping Using scRna Data (SIGURD) Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study An iPSC-derived myeloproliferative neoplasm model to study the role of CALR frameshift mutation zygosity and efficacy of telomerase inhibition Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) Exploiting Synthetic lethality between Germline BRCA1 haploinsufficiency and PARP inhibition in JAK2V617F-positive myeloproliferative neoplasms Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria Kit D816V mast cells derived from induced pluripotent stem cells recapitulate systemic mastocytosis transcriptional profile Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model Outcome of 129 Pregnancies in Polycythemia Vera Patients : A Report of the European LeukemiaNET Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals : analysis on 6849 participants of the SHIP-study Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group Breakthrough infections in MPN-COVID vaccinated patients Breakthrough infections in MPN-COVID vaccinated patients Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera : futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia S2k guideline: Diagnosis and treatment of chronic pruritus Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms: implications from the German study group for MPN bioregistry Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German Expert Consensus Panel with focus on cardiovascular management Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling Influence of the JAK2-V617F mutation on integrin-mediated adhesion to VCAM1 in murine and human cell lines in the context of classical Philadelphia-negative myeloproliferative neoplasms Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML) Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML) Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH) Diagnostik und Therapie der Polycythaemia vera im Jahre 2015 Diagnostik und Therapie der Polycythaemia vera im Jahre 2015 A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia - a randomised SAL pilot study

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Steffen Koschmieder (1971-)

Cell Adhesion and Local Cytokine Control on Protein‐Functionalized PNIPAM‐co‐AAc Hydrogel Microcarriers

Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells

Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms

Cell Adhesion and Local Cytokine Control on Protein‐Functionalized PNIPAM‐co‐AAc Hydrogel Microcarriers

Elucidating the complexity of the interferon alpha response and clonal heterogeneity in polycythemia vera patients using single-cell RNA sequencing

Regulation of lipocalin 2 expression and function in BCR-ABL- and JAK2V617F-positive myeloproliferative neoplasms

SIngle cell level Genotyping Using scRna Data (SIGURD)

Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study

An iPSC-derived myeloproliferative neoplasm model to study the role of CALR frameshift mutation zygosity and efficacy of telomerase inhibition

Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α : a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

Exploiting Synthetic lethality between Germline BRCA1 haploinsufficiency and PARP inhibition in JAK2V617F-positive myeloproliferative neoplasms

Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria

Kit D816V mast cells derived from induced pluripotent stem cells recapitulate systemic mastocytosis transcriptional profile

Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model

Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model

Outcome of 129 Pregnancies in Polycythemia Vera Patients : A Report of the European LeukemiaNET

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals : analysis on 6849 participants of the SHIP-study

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Breakthrough infections in MPN-COVID vaccinated patients

Breakthrough infections in MPN-COVID vaccinated patients

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera : futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia

S2k guideline: Diagnosis and treatment of chronic pruritus

Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms: implications from the German study group for MPN bioregistry

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry

Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm

Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management

Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita

Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita

Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita

Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm

Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German Expert Consensus Panel with focus on cardiovascular management

Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling

Influence of the JAK2-V617F mutation on integrin-mediated adhesion to VCAM1 in murine and human cell lines in the context of classical Philadelphia-negative myeloproliferative neoplasms

Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML)

Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML)

Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey

Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)

Diagnostik und Therapie der Polycythaemia vera im Jahre 2015

Diagnostik und Therapie der Polycythaemia vera im Jahre 2015

A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis

A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia

Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia - a randomised SAL pilot study